Clinical trial
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in…
NCT00035035 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00035035 |
|---|---|
| Title | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. |
| Official title | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | GEMZAR, ALIMTA |
| First posted | May 3, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | Argentina, Australia, Austria, Belgium, Colombia, France, Germany, Greece, Italy, Netherlands, Peru, Portugal and 6 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: